Authorization

Sartorius closes 2020 with strong growth to well over 2 billion euros and a further increase in profitability

GOTTINGEN, Germany, Jan. 27, 2021 /PRNewswire/ -- The life science group Sartorius recorded high growth according to preliminary figures in 2020 due to strong organic development, several acquisitions and the additional momentum from business related to the coronavirus pandemic. The Group closed the year with significant double-digit growth rates in sales revenue, order intake1 and earnings, reporting further gains in both divisions and across all geographies. "The pandemic year of 2020 was exceptional and very challenging for Sartorius as well. First and foremost, we are glad that we did not have to report any high numbers of infections or serious illnesses among our employees to report. Moreover, in a very intense and demanding environment, we also experienced the strongest year of growth in the company's recent history and were simultaneously able to complete several strategically important acquisitions," said Executive Board Chairman and CEO Joachim Kreuzburg. "Our strategy and business model proved not only to be particularly resilient in the face of the pandemic. Sartorius has also been contributing directly toward overcoming this pandemic: each and every day, we deliver essential products and technologies to vaccine manufacturers all over the world for producing coronavirus vaccines. Our employees mastered considerable challenges in the past year. A big thank you goes out to the entire international Sartorius team for the fantastic job they did.""Looking at the current year and ahead to the future, Kreuzburg remains generally optimistic: "The pandemic is still not over so protecting the health of our employees continues to remain our top priority. In this environment, even short-term forecasts are subject to increased uncertainty. Yet from today's perspective, we expect strong growth for 2021 and beyond. That's why we will accelerate and extend the expansion of our production capacities once again, above all at our sites in Germany, Puerto Rico, and China. Moreover, we considerably raised our mid-term targets for 2025 and now plan to grow our sales to about 5 billion euros."Business development of the GroupAccording to preliminary figures, Group sales revenue surged by 30.2A percent to nearly 2,336A million euros in constant currencies (reported: +27.8A percent). Sartorius thus exceeded its forecast issued at the beginning of the year, which had projected an increase in sales revenue by 10A percent to 13A percent and had been raised during the year. Specifically, this was because of two effects: In addition to strong organic growth, consolidation of the most recent acquisitions contributed a good 7A percentage points to non-organic expansion. Furthermore, the preparations of several biopharmaceutical customers to manufacture coronavirus vaccines and Covida??19 therapeutics also had a positive impact. The influence of these pandemic-related effects on consolidated growth was a good 8A percentage points.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Март 2021    »
ПнВтСрЧтПтСбВс
1234567
891011121314
15161718192021
22232425262728
293031